brain research center 370.
(photo credit: Hebrew University)
Intec Pharma Ltd. has obtained a $750,000 grant from the Michael J Fox
Foundation for Parkinson’s research. Intec Pharma has developed a new delivery
method for Levodopa, the leading treatment for the disease.
effective but does not last long in the bloodstream, and it must therefore be
given in large doses, resulting in side effects. Intec Pharma’s accordion
capsule releases the drug gradually, extending its effectiveness and lowering
the dosage. The company successfully conducted a phase-2 clinical trial of the
drug and is seeking a partner to commercialize it.
The Michael J Fox
Foundation makes grants of up to $1 million a year. Two other Israeli companies
have previously received grants: Neuroderm Ltd., which has received two grants;
and Proneuron Biotechnologies, which has gone out of business.
Pharma’s share price fell 0.4 percent to NIS 1.36 on Sunday, giving it a market
cap of NIS 292m.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>